



ASX RELEASE
(ASX : RSH)

Monday 29 February 2016

AirSonea® 3

Directors are pleased to advise that the company's engineering and software development continued throughout the period to ensure our AirSonea home monitoring product remains at the leading edge of respiratory monitoring technology. Extensive independent testing identified bug fixes to improve the performance of the AirSonea device handset and significant firmware updates were made during the half-year. This product is now best labelled **AirSonea® 3**.

Technology Waves: Self-monitoring of Complex Diseases, the Internet of things (IoT) and Partnership Opportunities

Directors are confident that Respiri technology has all the key components to participate in the technology waves beyond the current global phenomenon of health and wellness trackers; sensors to capture and transmit data, patented innovative software to detect and measure a chronic disease symptom and cloud computing to link and share data on IoT platforms. This technology platform makes Respiri an attractive partner for Technology, Big Pharma and Respiratory companies.

Research Study

Our AirSonea 3 device handset is now ready for market pilots with a large national pharmacy group once the University of Chicago Research study is completed. Shareholders have previously been advised that the study hypothesis is that AirSonea is at least as accurate in the detecting and quantifying wheeze as a consensus of physicians and a panel of technical experts who evaluate the recordings of breath sounds. The study commenced in January 2016 and the duration of the protocol is anticipated to be six months.

Proposed Rights Issue

The company is well advanced in relation to a proposed rights issue to provide working capital and further advance commercialisation. The rights issue is expected to be launched in March 2016 and is noted in the Company's Appendix 4D. Patersons Securities has been mandated to lead manage the offer which will aim to raise approximately \$3 million.

The company is pleased to advise that it has received letters of intent from the major shareholder and all the directors of the company confirming their intention to invest in the company through the rights issue in an aggregate amount of up to \$1.1 Million. Comprehensive details in relation to the proposed offer will be released in due course when available.

Contact:

Mr. Peter Vaughan
Company Secretary
Respiri Limited
1800 476 683